View in EDS HTML Full Text PDF Full Text

Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.

Saved in:
Bibliographic Details
Title: Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Authors: Robbrecht, Debbie1 (AUTHOR), Grob, Jean‐Jacques2 (AUTHOR), Bechter, Oliver3 (AUTHOR), Simonelli, Matteo4,5 (AUTHOR), Doger, Bernard6 (AUTHOR), Borbath, Ivan7 (AUTHOR), Butler, Marcus O.8 (AUTHOR), Cheng, Tina9 (AUTHOR), Romano, Patricia Martin10 (AUTHOR), Pons‐Tostivint, Elvire11 (AUTHOR), Di Nicola, Massimo12 (AUTHOR), Curigliano, Giuseppe13,14 (AUTHOR), Ryu, Min‐Hee15 (AUTHOR), Rodriguez‐Vida, Alejo16 (AUTHOR), Schadendorf, Dirk17,18,19,20 (AUTHOR), Garralda, Elena21 (AUTHOR), Abbadessa, Giovanni22 (AUTHOR), Demers, Brigitte23 (AUTHOR), Amrate, Amele23 (AUTHOR), Wang, Hong24 (AUTHOR)
Source: CTS: Clinical & Translational Science. Feb2024, Vol. 17 Issue 2, p1-11. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:17528054
DOI:10.1111/cts.13736